Discover
Alofisel (darvadstrocel) / TakedaADMIRE-CD: Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease (clinicaltrials.gov) - Nov 29, 2019 - P3; N=278; Completed; Sponsor: Tigenix S.A.U.; Active, not recruiting --> CompletedAlofisel (darvadstrocel) / TakedaLong-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula (clinicaltrials.gov) - Nov 29, 2019 - P3; N=150; Recruiting; Sponsor: Millennium Pharmaceuticals, Inc.; Not yet recruiting --> RecruitingHumira (adalimumab) / Eisai, AbbVieHumira pricing: RMB3,160/40mg injection (BUYSELLSIGNALS RESEARCH) - Nov 30, 2019 - A subscription to Thomson ONE is required to gain full access to report 68415684; Page no: 40; REPORT TITLE: "Shanghai Henlius Biotech Co Ltd- Shanghai Henlius Biotech plummets 9% in past month”; AUTHOR: Research Team, et al; DATE: 11/27/2019Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi sales projection: $3.3B in 2025 (UBS) - Nov 27, 2019 - A subscription to Thomson ONE is required to gain full access to report 68367849; Page no: 2; REPORT TITLE: "AbbVie "Greater certainty to key growth assets – PT to $96" (Buy) Jacob”; AUTHOR: Jacob, Navin, et al; DATE: 11/18/2019Tremfya (guselkumab) / J&JTremfya sales projection: $4.6B in 2029 (Guggenheim) - Nov 28, 2019 - A subscription to Thomson ONE is required to gain full access to report 68374268; Page no: 71; REPORT TITLE: "Initiating coverage: Innovative oncology antibody platforms-next leg of industry growth not a three-legged stool”; AUTHOR: Darout, Etzer, et al; DATE: 11/19/2019Otezla (apremilast) / AmgenOtezla sales projection: $2.7B in 2022 (Cowen & Co) - Nov 26, 2019 - A subscription to Thomson ONE is required to gain full access to report 68386681; Page no: 2; REPORT TITLE: "Celgene Corp - Discontinuing coverage”; AUTHOR: Werber, Md, Yaron, et al; DATE: 11/21/2019filgotinib (GLPG0634) / GileadFilgotinib WW sales projection: $2B peak for rheumatoid arthritis and IBD (Jefferies) - Nov 29, 2019 - A subscription to Thomson ONE is required to gain full access to report 68348316; Page no: 5; REPORT TITLE: "Galapagos NV: Filgotinib, Toledo and IPF in focus with key IPF interim later than hoped”; AUTHOR: Welford, Peter, et al; DATE: 11/14/2019Rinvoq (upadacitinib) / AbbVieRinvoq US sales projection: $39M (consensus: $41M) in FY2019 (UBS) - Nov 30, 2019 - A subscription to Thomson ONE is required to gain full access to report 68354122; Page no: 4; REPORT TITLE: "US Pharmaceuticals "*New* Rinvoq - Drug launches – Weekly tracker" Jacob”; AUTHOR: Jacob, Navin, et al; DATE: 11/15/2019Xeljanz (tofacitinib) / PfizerXeljanz patent expiry: Related to enantiomer in 2022 and related to polymorphic form in 2023 (Corporate Watchdog) - Nov 29, 2019 - A subscription to Thomson ONE is required to gain full access to report 68393470; Page no: 26; REPORT TITLE: "Pfizer Inc. - Watchdog report: PFE - Red flags and warning signs”; AUTHOR: Research Department; DATE: 11/22/2019Humira (adalimumab) / Eisai, AbbVieChina updates drug reimbursement list, agrees price cuts (PMLive) - Nov 29, 2019 - “Chinese regulators have added 70 new medicines to the country’s National Reimbursement Drug List (NRDL), and has agreed an average of 61% in price cuts with pharma companies. The key drugs which have been added to the list include AbbVie’s blockbuster drug Humira (adalimumab), Novartis’ dermatitis drug Xolair (omalizumab)…. According the NHSA, Chinese citizens can use their state medical insurance to cover a significant amount of the cost of the drugs added to the list."
